PROK logo

PROK
ProKidney Corp

1,858
Mkt Cap
$562.56M
Volume
19.00
52W High
$7.13
52W Low
$0.4603
PE Ratio
-3.43
PROK Fundamentals
Price
$1.87
Prev Close
$1.73
Open
$1.74
50D MA
$2.23
Beta
2.37
Avg. Volume
1.05M
EPS (Annual)
-$0.6249
P/B
-0.25
Rev/Employee
$372.55
Loading...
Loading...
News
all
press releases
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of "Hold" from Analysts
ProKidney Corp. (NASDAQ:PROK - Get Free Report) has received a consensus recommendation of "Hold" from the seven ratings firms that are covering the company, MarketBeat.com reports. Two investment...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
ProKidney (NASDAQ:PROK) Stock Price Down 5.5% - What's Next?
ProKidney (NASDAQ:PROK) Shares Down 5.5% - Here's What Happened...
MarketBeat·25d ago
News Placeholder
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by Analysts
ProKidney Corp. (NASDAQ:PROK - Get Free Report) has been assigned a consensus recommendation of "Hold" from the seven research firms that are covering the company, Marketbeat.com reports. Two...
MarketBeat·1mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Shares Down 7.3% - Should You Sell?
ProKidney (NASDAQ:PROK) Shares Down 7.3% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Stock Price Down 4.3% - What's Next?
ProKidney (NASDAQ:PROK) Stock Price Down 4.3% - Should You Sell...
MarketBeat·2mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Stock Price Up 5.2% - What's Next?
ProKidney (NASDAQ:PROK) Trading Up 5.2% - Still a Buy...
MarketBeat·2mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at HC Wainwright
HC Wainwright initiated coverage on ProKidney in a report on Tuesday. They issued a "buy" rating and a $12.00 target price for the company...
MarketBeat·2mo ago
News Placeholder
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy PR Newswire VANCOUVER, BC, Dec. 16, 2025 Issued on behalf of Avant...
PR Newswire·2mo ago
News Placeholder
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts
ProKidney Corp. (NASDAQ:PROK - Get Free Report) has received a consensus rating of "Hold" from the six brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have...
MarketBeat·2mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Trading Down 6.8% - What's Next?
ProKidney (NASDAQ:PROK) Trading Down 6.8% - Time to Sell...
MarketBeat·2mo ago
<
1
2
...
>

Latest PROK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.